News and Announcements
SUDA Files Patent Application For Novel Mucosal Penetration Technology
- Published November 03, 2016 5:08PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
2 November 2016, ASX Announcment
SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announced that it has filed a provisional patent application with IP Australia for a novel mucosal penetration drug delivery technology. The application was filed under the international Patent Cooperation Treaty (PCT), which enables SUDA to seek patent protection for its technology in more than 145 countries.
The technical field of the provisional patent application is entitled: ‘A method for modifying the penetration of active agents through mucosal membranes using hydrotopes.’
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
